TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$200 Million



Sole Placement Agent, May 2021


NeoGenomics, Inc. (“NeoGenomics” or the “Company”) is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers and others with innovative diagnostic, prognostic and predictive testing. NeoGenomics provides expert bone marrow and surgical pathology consulting. The Company has a network of CAP-accredited, CLIA-certified facilities in the U.S. and offers global capabilities with laboratories in Switzerland and Singapore.